Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2014

View Archived Issues

Scientists develop novel computational tool to rapidly detect genetic alterations in tumors

AbbVie highlights key events of third quarter 2014

Treatment with palmithoylethanolamide plus polydatin shows promise in patients with IBS

R-Pharm CJSC discloses new B7 ligands/CD20 inhibitors

University of Missouri patents novel SMN2 E-1 ASOs

Profectus receives DoD funding to support development of vaccines against Ebola and Marburg viruses

Novartis patent reports new NS4B inhibitors for dengue

Japanese team designs new FLT3 and/or Trk-A inhibitors

New autotaxin inhibitors patented by Lilly

AstraZeneca's acquisition of Almirall's respiratory business complete

Bristol-Myers Squibb to acquire Galecto Biotech and its novel galectin-3 inhibitor

Novel cephems reported by Shinogi

Geron confirms removal of full clinical hold on imetelstat IND

Myelofibrosis candidate PRM-151 receives fast track designation

Astellas Pharma offers overview of second quarter of fiscal 2014

DNA methylation differences found in children with forearm fractures

Antituberculosis food supplement Nyaditum resae evaluated in clinical trial

Theravance releases data from first cohorts of proof-of-concept study of TD-6450 for HCV

Myriad Genetics and AbbVie sign companion diagnostic agreement for BRACAnalysis

European COMP gives positive opinion on orphan drug designation for IVA-337 in systemic sclerosis

FDA clears IND for phase I/IIa study of OpRegen for geographic atrophy

arGEN-X files IND to begin study of ARGX-110 in Waldenstrom's macroglobulinemia

LabCorp to acquire Covance in early 2015

Eisai and Arena report phase II data for lorcaserin in smoking cessation

SUVN-G3031 begins phase I trial in the U.S.

NIMH creates new unit to support its research domain criteria initiative

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...